Compare Moderna, Inc. (MRNA) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Moderna, Inc. trades at $221.1 (market cap $78.65B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.9 (market cap $21.89B). The key difference: Moderna, Inc. is far larger — about 3.6× Consumer Discretionary Select Sector SPDR Fund's market cap, and Moderna, Inc. is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| MRNA | XLY | |
|---|---|---|
Market Cap | $78.65B | $21.89B |
Volume | 37,373,437 | 5,690,342 |
Sector | Health | — |
52-Week High | $203.46 | $124.52 |
52-Week Low | $22.36 | $105.64 |
Typical Hold Time | 59 Days | 114 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
XLY trades at $112.72, up 1.22% today, with a bullish technical signal despite mixed moving average and oscillator readings. The ETF shows strong analyst support with a 100% buy rating from coverage, though recent underperformance versus consumer staples highlights sector rotation pressures. Key technical levels show support at $110-$111 and resistance at $112-$113, with RSI indicating potential overbought conditions on shorter timeframes.
Outlook remains cautiously optimistic given analyst consensus, but investors face headwinds from inflation pressures on discretionary spending and ongoing underperformance versus broader market. The 'funflation' trend supporting consumer leisure spending provides potential upside, though valuation metrics remain unavailable for comprehensive assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
